Can a supercharged radiation boost stop lung cancer from returning?
NCT ID NCT02788461
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 36 times
Summary
This phase 2 trial is testing whether giving a higher dose of radiation to the most active parts of a lung tumor can lower the chance of the cancer coming back. About 78 people with locally advanced non-small cell lung cancer will receive either standard chemoradiation or a boosted radiation dose to their tumor's hot spots. The study aims to see if this personalized approach improves local control without causing too many extra side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Quebec - L'Hôtel-Dieu de Québec
Québec, Quebec, G2L 2Z3, Canada
-
CHUS - Hôpital Fleurimont
Sherbrooke, Quebec, J1H 5N4, Canada
-
Kingston General Hospital
Kingston, Ontario, K7L 2V7, Canada
-
London Regional Cancer Program
London, Ontario, N6A 4L6, Canada
-
McGill University Health Centre, Glen site Cedars Cancer Center
Montreal, Quebec, H4A 3J1, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Stronach Regional Cancer Centre at Southlake Regional Health Centre
Newmarket, Ontario, L3Y 2P9, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy (standard dose or higher boost dose) plus chemotherapy (cisplatin and etoposide)
What this could lead to
If it works, this could point toward a more effective way to deliver radiation for locally advanced lung cancer, potentially reducing the chance of the cancer coming back in the chest.
What could go wrong
This is a relatively small, early-phase trial, so results may not be definitive. The higher radiation dose could also increase side effects like lung inflammation or damage to nearby organs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.